Insider Selling: Immunocore (NASDAQ:IMCR) CAO Sells 698 Shares of Stock

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) CAO John Goll sold 698 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $22,580.30. Following the completion of the transaction, the chief accounting officer directly owned 653 shares in the company, valued at approximately $21,124.55. The trade was a 51.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Immunocore Price Performance

NASDAQ:IMCR traded up $0.66 during trading hours on Thursday, hitting $33.17. 392,220 shares of the company’s stock traded hands, compared to its average volume of 465,558. Immunocore Holdings PLC Sponsored ADR has a 52 week low of $23.15 and a 52 week high of $40.71. The business’s fifty day simple moving average is $33.94 and its two-hundred day simple moving average is $34.31. The company has a quick ratio of 5.97, a current ratio of 6.00 and a debt-to-equity ratio of 0.99. The firm has a market cap of $1.68 billion, a P/E ratio of -58.19 and a beta of 0.78.

Key Headlines Impacting Immunocore

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Immunocore will report fourth-quarter and full-year 2025 results and host an earnings call on Feb. 25 — a near-term catalyst that can drive volatility and provide fresh guidance. GlobeNewswire: Earnings Release
• Neutral Sentiment: Short-interest data in the February snapshot shows zero shares short and a 0.0 days-to-cover figure — this appears anomalous and is likely a reporting error, so it should not be treated as a clear bullish signal.
• Negative Sentiment: CEO Bahija Jallal sold 11,474 shares at an average price of $32.35 (about $371k), cutting her holding roughly in half — a sizable insider sell that can weigh on sentiment. SEC Filing — CEO Sale
• Negative Sentiment: CFO/CAO John Goll sold 698 shares at $32.35, reducing his stake by ~52% — another insider reduction that may prompt investor questions about timing. SEC Filing — CAO Sale
• Negative Sentiment: Senior exec David M. Berman sold 5,965 shares at $32.35 (~$193k), cutting his position by about half — contributes to the cluster of insider selling. SEC Filing — Insider Sale
• Negative Sentiment: Leger Tina Amber St sold 1,000 shares at $32.35, also materially reducing her stake — another data point of concentrated insider selling on Feb. 18. SEC Filing — Insider Sale

Hedge Funds Weigh In On Immunocore

Several institutional investors and hedge funds have recently made changes to their positions in IMCR. Royal Bank of Canada lifted its stake in Immunocore by 45.1% in the first quarter. Royal Bank of Canada now owns 44,011 shares of the company’s stock worth $1,306,000 after purchasing an additional 13,689 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of Immunocore by 4,696.3% during the second quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock valued at $41,000 after buying an additional 1,268 shares during the last quarter. State of New Jersey Common Pension Fund D purchased a new position in shares of Immunocore in the second quarter worth about $292,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Immunocore in the 2nd quarter valued at about $1,621,000. Finally, Assetmark Inc. boosted its holdings in Immunocore by 3.7% during the 2nd quarter. Assetmark Inc. now owns 34,958 shares of the company’s stock valued at $1,097,000 after acquiring an additional 1,248 shares during the period. Institutional investors own 84.50% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on IMCR. Mizuho set a $38.00 price objective on shares of Immunocore in a research report on Thursday. UBS Group set a $55.00 price target on shares of Immunocore and gave the stock a “buy” rating in a report on Wednesday, January 7th. Wells Fargo & Company assumed coverage on shares of Immunocore in a research report on Friday, October 31st. They set an “overweight” rating and a $60.00 price objective on the stock. Morgan Stanley upped their target price on shares of Immunocore from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research report on Monday, November 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research note on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.90.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.